๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Nashik
Clinical trial register · India

Clinical Trials in Nashik

Every study on the ClinicalTrials.gov registry that lists a site in India and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 1123 matching records held by the registry are in this view. Synced 21 Sep 2026, 03:16 UTC
1123
Studies in scope
all four open statuses
610
Recruiting now
open to new participants
222
Lead sponsors
across recruiting studies
Top sites
New Delhi 332 Mumbai 259 Hyderabad 237 Bangalore 193 Pune 189
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca29 Eli Lilly and Company9 Novartis Pharmaceuticals8 Pfizer8 Janssen Research & Development, LLC5
Site location
New Delhi332 Mumbai259 Hyderabad237 Bangalore193 Pune189
All 274 locations
Target enrolment
to
99 of 1123 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Indian sites
Start
Not yet open
A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In India
NCT07459543Unresectable Melanoma, Metastatic Melanoma
Bristol-Myers Squibb
Phase 4
40
Nashik, Mumbai, Navi Mumbai, Pune, Bhubaneswar, Chennai, Nagpur, New Delhi
2026-11-15
Not yet open
Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
NCT07816666Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer, Platinum-sensitive Relapsed Primary Peritoneal Cancer
AstraZeneca
Phase 3
600
Ahmedabad, Bangalore, Gurgaon, Kottayam, Madurai, Nashik, New Delhi, Vadodara
2026-09-29
Not yet open
A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder
NCT07285798Irritability Associated With Autism Spectrum Disorder
Bristol-Myers Squibb
Phase 3
176
Belgavi, Kozhikode, Nashik, Sakri, Kolkata, Nagpur, New Delhi
2026-09-11
Not yet open
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
NCT07668336Diabetes Mellitus, Type 2
Eli Lilly and Company
Phase 3
170
Ahmedabad, Aligarh, Bhubaneswar, Guntur, Mumbai, Nashik, New Delhi
2026-09
Recruiting
A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
NCT07754461Type 2 Diabetes
Boehringer Ingelheim
Phase 3
600
Ahmedabad, Bhubaneswar, Cuttack, Hyderabad, Afzalgunj, Kolhฤpur, Lucknow, Nagpur, Nashik
2026-08-24
Recruiting
A Clinical Trial to Assess the Effect of AP-Brain Collagen Peptides on the Improvement of Attention, Focus, and Memory in Stressed But Otherwise Healthy Individuals
NCT07572240Healthy, Stress
Rousselot BVBA
Not applicable
72
Nashik, Navi Mumbai, Pimpri-Chinchwad, Pune, Thane
2026-07-27
Recruiting
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
NCT07720284High-risk Muscle Invasive Urothelial Carcinoma
AstraZeneca
Phase 3
915
Kolkata, Kottayam, Nashik, Navi Mumbai, New Delhi
2026-07-16
Recruiting
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting
NCT07613307Diabetes Mellitus, Type 2, Diabetes Melletus, Glucose Metabolism Disorders, Metabolic Disorders
Eli Lilly and Company
Phase 3
130
Agra, Hyderabad, Kanpur, Kolkata, Mumbai, Mysore, Nashik, Nellore
2026-07-15
Recruiting
A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreF
NCT07653100Respiratory Syncytial Virus (RSV)
Pfizer
Phase 3
540
Visakhapatnam, Bangalore, Belagavi, Nashik, Dwarka, New Delhi, Jaipur, Chengalpattu
2026-06-22
Recruiting
Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency
NCT06948214Growth Hormone Deficiency (GHD)
Lumos Pharma
Phase 3
150
Mumbai, Nashik, Jaipur, Madurai, Chandigarh
2026-05-20
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
NCT07221149Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Bristol-Myers Squibb
Phase 2/3
690
Nashik, Mumbai, Delhi, Puducherry, Pune
2026-03-13
Recruiting
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
NCT07431177Non-segmental Vitiligo
Novartis Pharmaceuticals
Phase 2
210
Ahmedabad, Bangalore, Belagavi, Mysore, Nashik
2026-03-09
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
NCT07321886Obesity, Overweight
Eli Lilly and Company
Phase 3
1,980
Guntur, Guwahati, Hyderabad, Mandya, Mumbai, Mysore, Nagpur, Nashik
2026-02-06
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
Pfizer
Phase 3
1,410
Surat, Vadodara, Gurugram, Bangalore, Belagavi, Kottayam, Nagpur, Nashik
2026-01-06
Recruiting
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
NCT07063745Metastatic Non-small Cell Lung Cancer With MTAP Deletion
Bristol-Myers Squibb
Phase 2/3
590
Bangalore, Bengaluru, Mumbai, Nashik, New Delhi, Varanasi, Hyderabad
2026-01-02
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
NCT07221357Untreated, Unresectable, or Metastatic Colorectal Cancer
Bristol-Myers Squibb
Phase 2/3
990
Nashik, Thiruvananthapuram, Mumbai, Delhi, Puducherry, Pune
2025-12-31
Recruiting
AZD5335 vs. Mirvetuximab Soravtansine in FRฮฑ-high and AZD5335 vs. Chemotherapy in FRฮฑ-low Platinum-resistant Ovarian Cancer
NCT07218809Epithelial Ovarian Cancer
AstraZeneca
Phase 3
1,100
Bhubaneswar, Chennai, Delhi, Dhanvantari Nagar, Kolkata, Nagpur, Nashik, Surat
2025-12-29
Recruiting
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
NCT07221253Biliary Tract Cancer
AstraZeneca
Phase 3
1,100
Delhi, Hyderabad, Kolhฤpur, Kolkata, Mumbai, Nashik, Surat
2025-12-04
Recruiting
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
NCT07276399Squamous Cell Carcinoma of Head and Neck
Janssen Research & Development, LLC
Phase 3
500
Chennai, Jaipur, Kolkata, Nashik, New Delhi, Vadodara
2025-12-03
By invitation
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
NCT07256392Chronic Spontaneous Urticaria
Celldex Therapeutics
Phase 3
1,370
Nagpur, Nashik, Pune
2025-11-25
Recruiting
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
NCT07291037Non-small Cell Lung Cancer (NSCLC)
AstraZeneca
Phase 3
400
Bangalore, Kolkata, Mumbai, Nashik, New Delhi
2025-10-31
Recruiting
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
NCT07223593Peripheral Arterial Disease
Eli Lilly and Company
Phase 3
1,205
Aligarh, Jaipur, Kolkata, Kozhikode, Nagpur, Nashik, New Delhi, Rishikesh
2025-10-31
Recruiting
Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes
NCT07102628Acute Coronary Syndrome
Novartis Pharmaceuticals
Phase 3
300
Belagavi, Mumbai, Nashik, Bikaner
2025-10-03
Recruiting
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Eli Lilly and Company
Phase 3
10,450
Belagavi, Belgavi, Jaipur, Kanpur, Kozhikode, Lucknow, Nagpur, Nashik
2025-09-02
Recruiting
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
NCT07062965Breast Cancer
Pfizer
Phase 3
400
Surat, Bengaluru, Nashik, Pune
2025-08-05
Rows per page Showing 1–25 of 99
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Indian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 21 September 2026. https://priyalifescience.com/clinical-trials-india/city/nashik

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.